What is Rapport Therapeutics, Inc.'s revenue?

Rapport Therapeutics, Inc. (RAPP) reported revenue of $20M in Q1 2026.

Rapport Therapeutics, Inc. RAPP Revenue

Revenue at other companies

HTF

Heartflow, Inc. Common StockHTFL

$52.59M+41.3%

Cal-Maine FoodsCALM

$666.95M-53.0%

DJT

Trump Media & Technology GroupDJT

$871.2K+6.1%

ADMA BiologicsADMA

$114.49M-0.3%

Minerals TechnologiesMTX

$546.9M+11.2%

Lincoln Educational Services CorporationLINC

$143.96M+22.5%

Other financials

Income statement

See full

Revenue$20.0M—

Operating income-$24.2M+10.7%

Net income-$19.9M+17.5%

EPS (diluted)-$0.42+38.2%

Balance sheet

See full

Cash & equivalents$78.1M+35.5%

Total debt$10.8M+37.8%

Total equity$471.5M+65.0%

Total assets$497.6M+64.7%

Cash flow

See full

Operating cash flow-$13.1M+35.5%

CapEx$86.0K-70.4%

Free cash flow-$13.1M+36.0%

Valuation

See full

Market cap$1.91B+309%

Returns & leverage

See full

Return on equity-28.3%—

Debt / equity0×0.0×

Current ratio27.1×-3.9×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s revenue?: Rapport Therapeutics, Inc. (RAPP) reported revenue of $20M in Q1 2026.